Novartis said that an ongoing, internal review of adverse event reporting practices in the pharma’s Japanese Novartis Pharma K.K. (NPKK) business unit has revealed about 10,000 previously unreported individual case safety reports.
Read the full 328 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD